New Delhi, Jul 22 (UNI) Country's leading generic drugmaker, Ranbaxy Laboratories Ltd (Ranbaxy) today said the UK Serious Fraud Office's (SFO) prosecution of its UK subsidiary, Ranbaxy (UK) Ltd (RUKL), has been quashed by the English Crown Court.
The Court also declined an application by the SFO for permission to appeal to the English Court of Appeal, although the SFO retains a right to appeal to the Court of Appeal directly, a company statement said.
''Ranbaxy welcomes the decision of the English Crown Court.
Ranbaxy is a responsible company committed to providing high quality generic medicines at affordable prices to its customers and patients throughout the world,'' the statement added.
UNI PDT MP UCS1317